CPHRM Exam Dumps : Certified Professional in Health Care Risk Management (CPHRM)

Marketing claims can create liability exposure when they reasonably induce reliance and the patient suffers harm. Depending on jurisdiction and facts, plaintiffs may allegeapparent agency(belief that physicians acted as the HMO’s agents),vicarious liability, negligent credentialing, or negligent misrepresentation/consumer protection claims if statements are misleading. Risk management objectives include reviewing public claims for accuracy, ensuring marketing does not overpromise clinical capability, and aligning network adequacy and credentialing with representations. Clear disclosures about independent contractors may help but do not always defeat apparent agency claims. Controls include legal review of advertising, credentialing rigor, quality oversight, and complaint surveillance to detect mismatches between marketing and actual service capability.

EMTALA applies when an individual comes to the ED and requires a medical screening exam to determine whether anemergency medical condition (EMC)exists. Conditions like myocardial infarction, ruptured appendix, and unstable labor can constitute EMCs because absence of immediate medical attention could reasonably be expected to place health in serious jeopardy. By contrast,stable chronic kidney failurewithout acute destabilization may not meet the EMC threshold—though the screening exam must be performed before that determination is made. Risk management objectives emphasize: never “triage out” without an appropriate screening exam, document findings and decision-making, and apply consistent policies to avoid discriminatory practice. EMTALA failures often stem from process breakdowns (delays, refusal, inadequate screening, improper transfer), so standardized ED workflows and training are critical.

Under Health Care Risk Management standards supported by ASHRM and the American Hospital Association Certification Center, the implantation of a medical device that lacks FDA approval and Institutional Review Board oversight presents significant legal and regulatory violations. Use of an unapproved device outside of an approved investigational protocol may violate federal regulations governing human subject research and medical device approval processes.

The risk manager’s primary responsibility is to immediately mitigate regulatory and liability exposure. Because the procedure is scheduled for the next day, urgent intervention is required. Contacting the FDA would not resolve the immediate risk. Verifying informed consent is insufficient, as patient consent cannot legitimize use of an unapproved device outside regulatory pathways. Calling a special IRB meeting would not retroactively authorize an unapproved device without appropriate investigational device exemption processes.

Escalating the issue to the chief of surgery to halt or cancel the procedure is the most appropriate immediate step. This ensures that organizational leadership addresses the compliance violation before patient harm occurs. Risk management objectives emphasize proactive prevention of regulatory breaches, protection of patient safety, and preservation of institutional integrity. Therefore, stopping the procedure is the correct and immediate action.